Modern Authentication of Pharmaceuticals Act of 2025
- Bill Number
- H.R. 1060
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-06: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-04-08T17:28:33Z
AI-Generated Summary
Purpose
The Modern Authentication of Pharmaceuticals Act of 2025 aims to update the ways controlled substances—drugs regulated due to their potential for abuse, like certain painkillers or stimulants—are verified as genuine within the U.S. pharmaceutical supply chain. By requiring new authentication methods, the law seeks to prevent counterfeiting and ensure drug safety from manufacturing to dispensing.
Key Provisions
- Requirement for Physical Chemical Identifiers: Starting five years after the law's enactment, every dose of a controlled substance in solid oral dosage form (e.g., pills or tablets) must include a physical chemical identifier. This is a unique substance or mix of substances embedded in or on the drug, designed to be machine-readable and used to confirm authenticity.
- Expanded Definition of Product Identifier: The term now includes either:
- A standardized graphic (like a barcode) with the drug's numerical code, lot number (batch identifier), and expiration date; or
- The new physical chemical identifier.
- Updated Verification Process: "Verification" now means checking either the graphic identifier against manufacturer records or using technology to detect the physical chemical identifier to ensure the drug or its dosage form is real.
Significant Changes to Existing Law
- Amends Section 582(a)(9) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) by adding the physical chemical identifier requirement specifically for controlled substances in solid oral forms, building on existing rules for serialized tracking.
- Revises definitions in Sections 581(14) and 581(28) of the FD&C Act to incorporate physical chemical identifiers alongside traditional barcodes, making authentication more flexible and technology-driven.
- These changes expand beyond current graphic-based systems (introduced in the 2013 Drug Supply Chain Security Act) to include chemical-based methods, but only apply to new manufacturing of specified controlled substances.
Potential Impacts
- On Government Agencies: The Food and Drug Administration (FDA) will need to oversee compliance, potentially updating guidance, inspection protocols, and enforcement for the new identifiers, which could increase administrative workload but improve supply chain monitoring.
- On Citizens: Patients relying on controlled substances may benefit from reduced risk of counterfeit drugs, leading to safer treatments and fewer health risks from fakes. However, any added costs could indirectly raise drug prices.
- On International Relations: Minimal direct impact, though it may influence global standards for pharmaceutical authentication if U.S. manufacturers exporting drugs adopt these methods, potentially pressuring international partners to align.
Main Stakeholders Affected
- Pharmaceutical Manufacturers and Repackagers: Must implement and embed physical chemical identifiers in production, incurring potential costs for new technology and retooling.
- Distributors and Pharmacies: Responsible for verifying authenticity using the new methods during handling and dispensing, requiring updates to scanning or testing equipment.
- Healthcare Providers and Patients: Gain enhanced drug safety, particularly for those prescribed controlled substances like opioids.
- FDA and Regulators: Tasked with enforcement, rulemaking, and ensuring the supply chain's integrity.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens the FD&C Act's framework for drug security without creating new penalties, relying on existing FDA authority; may lead to future litigation over compliance costs or identifier effectiveness.
- Constitutional: No apparent challenges, as it regulates interstate commerce in pharmaceuticals, a well-established federal power under the Commerce Clause.
- Political: Supports bipartisan efforts to combat the opioid crisis and drug counterfeiting by modernizing outdated systems; could face industry pushback on implementation timelines or expenses, but aligns with public health priorities.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Davis, Donald G. [D-NC-1]
Cosponsors (3)
Rep. Rutherford, John H. [R-FL-5], Rep. Bacon, Don [R-NE-2], Rep. Fitzpatrick, Brian K. [R-PA-1]
Recent Actions
- 2025-02-06: Referred to the House Committee on Energy and Commerce.
- 2025-02-06: Introduced in House
- 2025-02-06: Sponsor introductory remarks on measure. (CR H519)
- 2025-02-06: Introduced in House
Bill Versions
- Modern Authentication of Pharmaceuticals Act of 2025 — issued 2025-02-06 — PDF (4 pages)